Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 251 to 275 of 334

Guidance and quality standards awaiting development
Title	Type
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]	Technology appraisal guidance
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454]	Technology appraisal guidance
Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520]	Technology appraisal guidance
Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]	Technology appraisal guidance
Secondary care management of malignant hypertension	Quality standard
Secukinumab for treating giant cell arteritis in people 50 years and over [TSID12163]	Technology appraisal guidance
Secukinumab for treating relapsed polymyalgia rheumatica [ID6599]	Technology appraisal guidance
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]	Technology appraisal guidance
Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with neurofibromatosis type 1 [ID6385]	Technology appraisal guidance
Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [TSID12250]	Technology appraisal guidance
Semaglutide for treating type 2 diabetes [ID1450]	Technology appraisal guidance
Setmelanotide for treating acquired hypothalamic obesity in people 4 years and older [ID6542]	Technology appraisal guidance
Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616]	Technology appraisal guidance
Shared decision-making: practical guidance for health and social care professionals	Quality standard
Sibeprenlimab for treating IgA nephropathy [ID6604]	Technology appraisal guidance
Sleep disordered breathing	Quality standard
Social work interventions for adults with complex needs (including learning disabilities) and mental health needs	Quality standard
Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536]	Technology appraisal guidance
Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621]	Technology appraisal guidance
Sotagliflozin for treating type 2 diabetes [ID1657]	Technology appraisal guidance
Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955]	Technology appraisal guidance
Staged bilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor	Interventional procedures guidance
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]	Technology appraisal guidance
STS101 for treating acute migraine [TSID11782]	Technology appraisal guidance
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]	Technology appraisal guidance

Results per page

10
25
50
All